Affiliated Treatment Facilities
University of Iowa Hospitals & Clinics
200 Hawkins Drive
Iowa City, IA 52242
01. Doctor Overview
Doctor Overview
Dr. Clamon has various specialties, including lung cancers. He has been affiliated with the esophageal cancer, lung cancer, and head and neck cancer clinics at the Holden Comprehensive Cancer Center at the University of Iowa Hospitals and Clinics, the only NCI-designated comprehensive center in the state of Iowa. Much of Dr. Clamon’s expertise can be seen through his publications, many of which focus on lung cancers.
02. Fast Facts
Doctor Fast Facts
Main Specialty: Oncology
Other Interests & Specialties: Hematologic oncology, general oncology, esophageal cancer, lung cancer, and head and neck cancers.
Certifications, Awards & Accolades: American Board of Internal Medicine Certifications in Internal Medicine and Medical Oncology
Education & Experience:
- Residency for Internal Medicine at Washington University Barnes-Jewish Hospital
- Fellowship for Hematology at University of Iowa Hospitals and Clinics
- Internship for Internal Medicine at Washington University Barnes-Jewish Hospital
- Medical Degree from Washington University School of Medicine
03. Publications
Publications
High-dose paclitaxel plus G-CSF for malignant mesothelioma. Annals of Oncology. May 1999;10(5):597–600. doi: 10.1023/A:1026438215309
Effects of intravenous hyperalimentation during treatment in patients with small-cell lung cancer. Journal of Clinical Oncology. July 1985; 3(7): 949-957. doi: 10.1200/JCO.1985.3.7.949
Radiotherapy plus razoxane for advanced limited extent carcinoma of the lung. Cancer. June 1984;53(9):1852-6.
Effect of adjuvant central iv hyperalimentation on the survival and response to treatment of patients with small cell lung cancer: a randomized trial. Cancer Treatment Reports. February 1985;69(2):166-67.
Chemoprevention and screening for lung cancer: changing our focus to former smokers. Clinical Lung Cancer. January 2015;16(1):1-5. doi: 10.1016/j.cllc.2014.09.009
Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. Journal of Clinical Oncology. November 2013;31(33):4179-4187. doi: 10.1200/JCO.2013.49.2173
Relationship between HER-2 overexpression and brain metastasis in esophageal cancer patients. World Journal of Gastrointestinal Oncology. May 2012;4(5):103-108. doi: 10.4251/wjgo.v4.i5.103
Advances in the systemic treatment of leptomeningeal cancer. Clinical Advances in Hematology & Oncology. March 2012;10(3):166-170.
Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. Journal of Clinical Oncology. May 2010;28(13):2181-2190. doi: 10.1200/JCO.2009.26.2543